Inceptionr LLC Buys Shares of 21,450 STAAR Surgical Company $STAA

Inceptionr LLC purchased a new position in STAAR Surgical Company (NASDAQ:STAA) in the 1st quarter, Holdings Channel.com reports. The institutional investor purchased 21,450 shares of the medical instruments supplier’s stock, valued at approximately $401,000.

Several other hedge funds have also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in STAAR Surgical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after buying an additional 1,267 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in STAAR Surgical by 33.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock valued at $9,606,000 after acquiring an additional 136,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in STAAR Surgical by 11.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock valued at $2,175,000 after acquiring an additional 12,841 shares in the last quarter. Creative Planning increased its holdings in shares of STAAR Surgical by 19.9% in the 2nd quarter. Creative Planning now owns 15,695 shares of the medical instruments supplier’s stock valued at $263,000 after acquiring an additional 2,606 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of STAAR Surgical by 183.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 153,371 shares of the medical instruments supplier’s stock worth $2,574,000 after acquiring an additional 99,218 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on STAA shares. Canaccord Genuity Group upped their price objective on STAAR Surgical from $27.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Stifel Nicolaus lifted their target price on STAAR Surgical from $18.00 to $31.00 and gave the company a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of STAAR Surgical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 25th. Piper Sandler raised their price target on shares of STAAR Surgical from $16.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, Mizuho lifted their price objective on shares of STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $27.81.

STAAR Surgical Stock Performance

Shares of STAA opened at $23.38 on Monday. The company has a current ratio of 5.12, a quick ratio of 4.31 and a debt-to-equity ratio of 0.09. The firm has a market cap of $1.16 billion, a PE ratio of -54.37 and a beta of 1.23. STAAR Surgical Company has a 12 month low of $15.59 and a 12 month high of $35.87. The stock has a fifty day moving average price of $28.85 and a 200-day moving average price of $23.84.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, topping the consensus estimate of $0.05 by $0.05. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The business had revenue of $93.52 million during the quarter, compared to the consensus estimate of $78.72 million. During the same period in the previous year, the firm posted ($1.10) earnings per share. The business’s revenue for the quarter was up 119.6% compared to the same quarter last year. Equities research analysts predict that STAAR Surgical Company will post 0.13 earnings per share for the current fiscal year.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.